However, the diagnosis of end stage renal disease is validated since medical reimbursement of dialysis care is applied after quarterly reporting longitudinal laboratory data (such as measurement of dialysis clearance, hemoglobin, albumin, intact-PTH data) by attending physicians. The gene discussed is PTH; the disease is stage 5 chronic kidney disease.